109 related articles for article (PubMed ID: 12944919)
1. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec.
Trempat P; Villalva C; Laurent G; Armstrong F; Delsol G; Dastugue N; Brousset P
Oncogene; 2003 Aug; 22(36):5702-6. PubMed ID: 12944919
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
[TBL] [Abstract][Full Text] [Related]
3. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
4. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
6. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.
Wittman B; Horan J; Baxter J; Goldberg J; Felgar R; Baylor E; Cromwell B; Cross N; Bennett JM
Leuk Res; 2004 May; 28 Suppl 1():S65-9. PubMed ID: 15036944
[TBL] [Abstract][Full Text] [Related]
7. t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia.
Wang HY; Thorson JA; Broome HE; Rashidi HH; Curtin PT; Dell'Aquila ML
Hum Pathol; 2011 Dec; 42(12):2029-36. PubMed ID: 21676437
[TBL] [Abstract][Full Text] [Related]
8. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
Curtis CE; Grand FH; Musto P; Clark A; Murphy J; Perla G; Minervini MM; Stewart J; Reiter A; Cross NC
Br J Haematol; 2007 Jul; 138(1):77-81. PubMed ID: 17555450
[TBL] [Abstract][Full Text] [Related]
9. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
10. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.
Baxter EJ; Hochhaus A; Bolufer P; Reiter A; Fernandez JM; Senent L; Cervera J; Moscardo F; Sanz MA; Cross NC
Hum Mol Genet; 2002 Jun; 11(12):1391-7. PubMed ID: 12023981
[TBL] [Abstract][Full Text] [Related]
11. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia.
Sato N; Narita M; Takahashi M; Yagisawa K; Liu A; Abe T; Nikkuni K; Furukawa T; Toba K; Aizawa Y
Hematol Oncol; 2003 Jun; 21(2):67-75. PubMed ID: 12802811
[TBL] [Abstract][Full Text] [Related]
12. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
[TBL] [Abstract][Full Text] [Related]
13. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM
Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128
[TBL] [Abstract][Full Text] [Related]
14. Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.
Cluzeau T; Lippert E; Cayuela JM; Maarek O; Migeon M; Noguera ME; Dombret H; Rea D
Eur J Haematol; 2015 Nov; 95(5):480-3. PubMed ID: 25941032
[TBL] [Abstract][Full Text] [Related]
15. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
16. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Alvarez RH; Kantarjian H; Cortes JE
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S4-14. PubMed ID: 17292736
[TBL] [Abstract][Full Text] [Related]
17. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
18. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1.
Kwon HC; Kim SH; Kim JS; Han H; Roh MS; Han JY; Seo SY; Lee YH; Kim HJ
Cancer Genet Cytogenet; 2004 Oct; 154(1):52-6. PubMed ID: 15381372
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
